Increasing Atrial Base Rate Pacing to Reduce Atrial Fibrillation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
West-Azerbaijan
-
Urmia, West-Azerbaijan, Iran, Islamic Republic of
- Seyyed-al-Shohada Heart Center, UMSU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Sick sinus syndrome patients having dual-chamber pacemaker
- Having paroxysmal AF defined as at least 2 episodes of AHR/AMS >190 b/min lasting >6 minutes
- Having normal atrioventricular conduction
Exclusion Criteria:
- Other clinical indications for pacing except sick sinus syndrome (bradycardia-tachycardia syndrome)
- History of acute coronary syndrome
- Significant heart valve disease
- Chronic AF before randomization
- Overt heart failure
- Malignancy
- Any reasons for antiarrhythmic medication use
- Inability to follow patients every 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: High Atrial Base Rate Pacing
The base rate of pacemaker will be determined 75-100 beats/minute in condition that during first step of follow-up, his/her atrial pacing will be more than 80% of atrial high rate/automatic mode switch
|
Other Names:
|
|
ACTIVE_COMPARATOR: Device Default
The base rate of pacemaker will be determined 60 beats/minute
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Atrial high rate/Automatic mode switch episodes
Time Frame: During 6 Months
|
The number of AHR/AMS episodes recorded by pacemaker
|
During 6 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stroke
Time Frame: During 6 months
|
The development of stroke during follow-up
|
During 6 months
|
|
Myocardial infarction
Time Frame: During 6 months
|
The development of MI during follow-up confirmed by ischemic chest pain, 12-ECG, or cardiac enzyme elevation
|
During 6 months
|
|
Heart failure
Time Frame: During 6 months
|
The development or progression of heart failure during follow-up
|
During 6 months
|
|
Worsening Functional Class
Time Frame: During 6 months
|
The worsening of functional class
|
During 6 months
|
|
Death
Time Frame: During 6 months
|
Death
|
During 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UMSU-Cardiology-4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.